Michael O'Riordan retweeted
Safer Stroke Prevention in Atrial Fibrillation: Factor XI/XIa Inhibitors, Left Atrial Appendage Closure, or Both?
doi.org/10.1016/j.jacc.2026.…
Contributions from Baim CEO & President, @CMichaelGibson, and Baim faculty @TheMahaf and @lamcardio
#BaimInstitute #ClinicalResearch #AFib
SYNCHRONIZE-CVOT: Survodutide Passes Cardiovascular Safety Test cardiologynownews.org/?p=140…
129
REDUCE by @jordy_bc addresses suboptimal BP management post-stroke with adding spironolactone .
"What we’ve learned is that if they don’t leave the hospital on therapy, it’s not going to get started," said @MarcBonaca. @AHAScience @CMichaelGibson @BaimInstitute @CardioNowNews
REDUCE: Adding Spironolactone Reduces BP Over Usual Care in Stroke Patients cardiologynownews.org/?p=140…
257
REDUCE: Adding Spironolactone Reduces BP Over Usual Care in Stroke Patients cardiologynownews.org/?p=140…
Michael O'Riordan retweeted
American Heart Association now promoting a diagnostic misadventure that took an active, well man who could haul a kid + sled up a hill repeatedly in the cold with no symptoms and sending him to surgery and causing him months of pain and recovery
What is going on?!?
This quoted post is unavailable.
Michael O'Riordan retweeted
Aer Lingus has a new commercial….don’t tell @elonmusk as he may find the ad quite cunning…#ireland @AerLingus
Michael O'Riordan retweeted
🚨🚨A full issue of @JACCJournals about #LAAC in pts w #AF (#AFib), we have a #JACC Evidence review, and several other data reports, original research studies, and expert viewpoints. Let us know of your feedback! @MGBResearchNews
@hmkyale @aakriti_15
jacc.org/doi/10.1016/j.jacc.…
"We had one price to pay that offset the benefit, [which] was a potential increase in the composite renal endpoint," said @OtavioBerwanger. #AHA2026 @BaimInstitute @CardioNowNews @CMichaelGibson
OPTIMAL: Intensive BP Control Reduces Events After Stroke, Diabetes Trial Neutral cardiologynownews.org/?p=139…
1
179
OPTIMAL: Intensive BP Control Reduces Events After Stroke, Diabetes Trial Neutral cardiologynownews.org/?p=139…
Michael O'Riordan retweeted
Everyone defending Jensen is trying to make it about the sex.
It’s not about the sex.
It’s about how he enabled and even lobbied for Chinese AI, about how he subverted US policy, and how he carelessly left himself vulnerable to both blackmail and espionage.
And it’s about how he utterly blew off the problems inherent appearance of conflict of interest, to the peril of his company, his country, and his industry.
He also left Nvidia open to endless litigation and investigation (which is why they may be forced to fire him despite his immense talents).
The fact that he also slept with an employee is just icing on the cake, in a way that further emphasizes his poor judgment, and that would only make the shareholder lawsuits worse.
Firing him will be a huge blow, but keeping him on is no longer tenable, either.
Michael O'Riordan retweeted
I think that would be amazing and I think it’s not likely. The map of biology is still largely a blank page and randomized human proof is the long pole in the tent. I am excited about the use of AI in our sector but progress will likely be steady and incremental.
“Cancer, Alzheimer’s, heart disease, mental illness - these will be relics of the past in, I think, less than a decade.” — Anthropic CEO @DarioAmodei
What do you think, bio folks?
Source: instagram.com/reel/DfkundEE2…
Michael O'Riordan retweeted
Thx @Lpa_Doc for the thoughtful comments below
One item: can we move away from this "1 in 5 have high levels" mantra?
Has always been circular reasoning:
*Pick top quintile cutoff as "high" threshold (>50 mg/dl).
*Then, state that "1 in 5 have high levels".
Problem: risk for CV events at this threshold is very low.
Hazard ratio in secondary prevention for Lp(a) > 70 mg/dl is ~1.16.
At 50 mg/dl cutoff, risk would be even lower!
In HORIZON, it looks like baseline Lp(a) levels DID NOT PREDICT events in the placebo arm.
Here are my initial thoughts on Lp(a)HORIZON. This is targeted to the people to whom it matters the most, my wonderful PATIENTS over the years in my Lp(a) Clinic. I have done my best to keep you healthy, and for the most part it worked. And I think this is reflected in the results of the Lp(a)HORIZON trial. This is also for those with elevated Lp(a) that been carrying significant anxiety and concern over their elevated levels.
1- Big picture: I do not see Lp(a)HORIZON as a failure, like many Monday morning quarterbacks out there who claim to have known the results all along after all. I see it as a MAJOR SUCCESS for our patients.
2- Why? Because we learned that there may be an alternative to reduce Lp(a) mediated risk: which is to: a) keep LDL-C below 65 or lower; b) keep blood pressure at 120 or lower; c) control all other risk factors as best as possible; d) take your medicines that have proven efficacy regularly.
3- I have called Lp(a)HORIZON testing the “Lp(a) Hypothesis”. Which means we did not know if lowering Lp(a) would benefit patients. If we knew Novartis would not have spent >1 billion dollars to do the trial and the FDA would have approved the drug simply on Lp(a) lowering.
4- Why did we not see a benefit in specifically lowering Lp(a) in Lp(a)HORIZON? I think we need to go back to “first principles” in how Lp(a) causes atherothrombosis. It is a minor contributor to atherosclerosis. It is a major contributor to inflammation, via OxPL. It is also anti-fibrinolytic- NOT pro-thrombotic. That means it contributes to vulnerable plaques but not to “plaque burden”. And it contributes to a blood clots enlarging and occluding blood vessels if clots are already made, but not in making blood clots per se.
5- So if one is intensively treated to remove the nidus for vulnerable plaques and clot formation, like the patients in HORIZON (and in the ongoing trials), then Lp(a) may become quiescent.
6- In my Lp(a) Clinic, this is my summary of how I treat my patients: 75% on statin, 50% of ezetimibe and 50% (!!) on PCSK9i, along with judicious use of aspirin in primary prevention and universal use in secondary prevention. This double/triple/quadruple combo is highly effective. If I see no coronary calcium or evidence of atherosclerosis, I am not aggressive with therapy if otherwise not indicated for another reason.
7- That being said, 1 out of 8 people still had an event in Lp(a) HORIZON. So, we need to figure out why beyond classical lipids and blood pressure. I am already thinking 10 yrs ahead and will have new concepts for this issue in near future.
8- I do not think the Lp(a)HORIZON results apply to Aortic Stenosis, as this is not affected by LDL-C or for the most part aspirin, but is more @OxPL_apoB driven in people with high Lp(a).
I think we owe a huge debt of gratitude for the Lp(a)HORIZON trial, to @novartis and to @ionispharma for leading the Lp(a) field.
And to circle back to people with elevated Lp(a): Lp(a)HORIZON has now armed us with actionable (and inexpensive) knowledge to help people with elevated Lp(a). Take a big breath and sigh of relief, Lp(a) risk can be managed. Treat it like you do other risk factors and your prognosis will be good, like many of my Lp(a) Clinic patients. We do need to do more work to figure out, among those with elevated Lp(a), who are highest risk, and target those in future studies,
I will provide more scientific comments at a later time and will be publishing my thoughts in a journal in the future.
With all that said, we still don't know the physiological function of Lp(a), if any, and why >99.99% have some circulating Lp(a) and why 1 in 5 have very high levels. Knowing this may give us the ultimate answer on Lp(a) and it role not only in CV disease but also in life and longevity. Along with my collaborators, we will have something on this also in near future.
Thank you all for following Lp(a)'s journey in these pages. The story is actually in the middle not at the end...a few more chapters are in the works.
Michael O'Riordan retweeted
IRONMET-HFpEF: A Single Dose of IV Iron Improved Exercise Capacity in HFpEF With Iron Deficiency
Written by
@JNasrMD
More summary and analysis from #AHA2026 below: cardiologynownews.org/?p=139…
@CMichaelGibson @mpjORIORDAN @ceciliabahit
Michael O'Riordan retweeted
Cleaner Air Trial: Bedroom HEPA Filtration Lowered Glycemic Variability in Adults with Prediabetes
Written by
@JNasrMD
More summary and analysis from #AHA2026 below: cardiologynownews.org/?p=139…
@CMichaelGibson @mpjORIORDAN @ceciliabahit
Michael O'Riordan retweeted
COURAGE at 25-Year: Upfront PCI Does Not Reduce Long-Term Risk of Death or MI in Stable CAD
Written by
@Dranumijaz
More summary and analysis from #AHA2026 below: cardiologynownews.org/?p=139…
@CMichaelGibson @mpjORIORDAN @ceciliabahit
Michael O'Riordan retweeted
SUMMIT CMR Substudy: Tirzepatide Reduced RV Mass and Atrial Volumes in Obesity-Related HFpEF
Written by
@JNasrMD
More summary and analysis from #AHA2026 below: cardiologynownews.org/?p=139…
@CMichaelGibson @mpjORIORDAN @ceciliabahit
Michael O'Riordan retweeted
At some point, we have to ask whether our statistical definitions of acceptable harm have lost touch with what patients would actually consider acceptable.
STREAM: Stopping Statins ‘Noninferior’ to Continued Treatment, but Event Curves Diverge cardiologynownews.org/?p=139…
"We found that it was generally safe for the majority of older adults to stop statin therapy," said Nicolas Rodondi.
Others don't agree.
@BaimInstitute @CardioNowNews @CMichaelGibson @MichaelGNanna @Nishant_ShahMD @DukeHeartCenter @ACCinTouch #ACC2026
STREAM: Stopping Statins ‘Noninferior’ to Continued Treatment, but Event Curves Diverge cardiologynownews.org/?p=139…
STREAM: Stopping Statins ‘Noninferior’ to Continued Treatment, but Event Curves Diverge cardiologynownews.org/?p=139…
















